GlassScriptPhysician profile
Robin A Mcguire
NPI 1518064138
$1,260.72
in general payments reported to CMS, 2019-2025
19 companies · $49.65 in 2025
The $49.65 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $181 · 2021: $163 · 2022: $178 · 2023: $328 · 2024: $67.98 · 2025: $49.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.90 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $263.69 | 2019-2023 | Veozah |
| Abbvie INC. | $128.82 | 2019-2024 | |
| Organon LLC | $128.69 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $121.84 | 2019-2022 | |
| Pfizer INC. | $76.64 | 2019-2023 | |
| Shield Therapeutics INC | $63.74 | 2023 | Accrufer |
| Exeltis, USA INC. | $55.22 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $51.77 | 2021-2022 | |
| Urovant Sciences INC | $43.65 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $41.78 | 2023 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $41.54 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Currax Pharmaceuticals LLC | $41.48 | 2024-2025 | Contrave, Onzetra Xsail |
| Allergan, INC. | $41.13 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $40.93 | 2022-2023 | |
| Amgen INC. | $34.05 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $27.51 | 2020 | |
| Medicem INC. | $23.86 | 2023 | |
| Lilly USA, LLC | $21.64 | 2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.